Trial Profile
A study evaluating the safety, tolerability, and pharmacokinetics of MK-7655 dosed alone or in combination with a fixed dose of Imipenem/cilastatin
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2010
Price :
$35
*
At a glance
- Drugs Imipenem/cilastatin (Primary) ; Relebactam (Primary)
- Indications Bacterial infections
- Focus Adverse reactions
- 05 Nov 2010 New trial record.